Document is current
Any future updates will be listed below
-
Authors
Rasmussen, Nicklas H. https://orcid.org/0000-0002-3880-3058
Kvist, Annika Vestergaard
Bech, Asger Ahlmann
Lykkeboe, Simon
Starup-Linde, Jakob
Handberg, Aase
van den Bergh, Joop P.
Vestergaard, Peter
-
Funding
Funding for this research was provided by:
Danish Diabetes and Endocrine Academy (NNF22SA0079901)
Aalborg University Hospital
- License Information
-
More Information
Article History
Received: 9 June 2025
Accepted: 8 January 2026
First Online: 21 January 2026
Declarations
:
: The methods used have been tested and performed in several studies both in Denmark and abroad, and no long-term side effects have been reported. The risks associated with the project are few, and the tests implied limited risks. The potential benefits in terms of well-being were considerable and estimated to outweigh the potential risks. The study was reported to the local ethical committee in the North Jutland Region (N-2019–0004). The study was conducted in compliance with Harmonized Tripartite Guideline for Good Clinical Practice ( ICH GCP) and applicable regulatory requirements and in accordance with the Helsinki Declaration for biomedical research involving test participants. Finally, the project was reported to the North Jutland Research department (ID-number of 2018–174).
: Consent for each participant was achieved.
: Consent for each participant was achieved.
: Peter Vestergaard is head of research in the Steno Diabetes Center North Denmark, sponsored by the Novo Nordisk Foundation. Joop van den Bergh is involved in research that is sponsored by Amgen, Porous, and UCB. Jakob Starup-Linde holds lecture fees from Gedeon Richter Nordics AB and UCB Nordic A/S. Nicklas H. Rasmussen holds shares in Novo Nordisk and a grant from DDEA. Annika Vestergaard Kvist, Asger Ahlmann Bech, Simon Lykkeboe and Aase Handberg declare that she has no conflicts of interest.
